Neuroprotection in the PNS: Erythropoietin and immunophilin ligands

Ahmet Höke, Sanjay C. Keswani

Research output: Contribution to journalArticle

Abstract

Many illnesses that affect the peripheral nervous system (PNS) lead to distal axonal degeneration rather than loss of neuronal cell bodies. Strategies aimed at promoting survival of injured neurons (i.e., preventing cell death) may not be applicable to many PNS illnesses. We have developed in vitro and in vivo animal models to study mechanisms of acquired peripheral neuropathies and used these models to evaluate the therapeutic potential of novel compounds. In recent years, erythropoietin (EPO) lias been recognized as a novel neuroprotectant in the central nervous system. In the PNS, we recently showed that Schwann cell-derived EPO acts as an endogenous neuroprotectant and that it is most effective in preventing distal axonal degeneration seen in models of peripheral neuropathy. Similarly, we showed that immunophilin ligands are also neuroprotective in the PNS and prevent axonal degeneration seen in models of peripheral neuropathies. Both EPO and non-immunosuppressive immunophilin ligands are in early clinical development for the treatment of acquired peripheral neuropathies.

Original languageEnglish (US)
Pages (from-to)491-501
Number of pages11
JournalAnnals of the New York Academy of Sciences
Volume1053
DOIs
StatePublished - 2005

Keywords

  • Axonal degeneration
  • EPO
  • Erythropoietin
  • GPI-1046
  • Immunophilin ligands

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Fingerprint Dive into the research topics of 'Neuroprotection in the PNS: Erythropoietin and immunophilin ligands'. Together they form a unique fingerprint.

  • Cite this